Health

Aspartame is marketed as a diet product in many foods and beverages due to the fact that it allows food manufacturers to avoid using sugar, replacing it with an artificial substitute that they claim tastes like sugar.  However, the chemical sweetener consumed by millions worldwide is not an affective diet product at all. It can make you gain wait, and worst of all may be doing your health a lot of damage. Wakingscience.com reports: The woman in this story, who remains anonymous, is the sister of a writer who was featured on Rhonda Gessner’s blog.

As reported moments ago, Q1 GDP which came at just 0.5% growth, was a lousy number in which virtually every component besides personal spending (and government) subtracted from growth. In fact, in nominal terms, Q1 GDP grew only $22.2 billion annualized, of which personal consumption was more than double, or $52.5 billion.

But what did Americans spend money on in Q1? To our surprise, Healthcare, Obamacare was no longer what soaked up most Americans' cash in the first quarter (nonetheless, it was a runner up with $10.8 billion in spending).

The great megadeal M&A drought of 2016 just came to an end when moments ago Abbott announced it would acquire St. Jude Medical for $25 billion, roughly a 37% premium to St. Jude's Wednesday closing price. According to the press release, under the agreement, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share. At an Abbott stock price of $43.93(2), this represents a total transaction equity value of $25 billion.

Forget DOE data, it's time to buy ahead of The Fed!!

We suspect this won't last as the algos are struggling to catch the high stops.

2016 has been a tempestuous year for Serepta shareholders. From over $40 to just $10 and then the miracle ramp from february back to $25 before the writing on the wall ahead of last night's FDA decision and now - following yesterday's monstrous short-squeeze (36% surge), a 50% collapse to $8 - a 4 year low for yet another Biotech darling of old. This morning's collapse comes after the FDA voted that SRPT's muscular dystrophy drug was not effective...

As Bloomberg reports,